Navigation Links
GenVec Announces Third Quarter 2009 Results Conference Call
Date:10/28/2009

GAITHERSBURG, Md., Oct. 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the third quarter ended September 30, 2009 on Thursday, November 5, 2009 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, November 6, 2009 to discuss the company's third quarter results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

To listen to the live conference call, please dial 888-679-8040 (U.S. or Canada) or 617-213-4851 (international) and use access code 35178683. Participants may pre-register for the call anytime at:

https://www.theconferencingservice.com/prereg/key.process?key=PPCBK3H6R.

Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on November 6, 2009 through November 12, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 28987203.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    Investor Contact:            Media Contact:
    GenVec, Inc.                 Tiberend Strategic Advisors, Inc.
    Danielle M. DiPirro          Andrew Mielach
    (301) 944-1877               (212) 827-0020
    ddipirro@genvec.com          amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Expands Contract Supporting Malaria Vaccine Program
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
7. TOPAZ Technologies Announces SoBran Inc. as New Customer
8. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
9. LPBP Inc. announces final distribution
10. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
11. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):